Cause-specific mortality in classic Kaposi's sarcoma: a population-based study in Italy (1995-2002).
BACKGROUND
Little information is available on the causes of death among persons with classic Kaposi's sarcoma (CKS).


METHODS
We conducted a population-based study in Italy to identify deceased persons with CKS and the underlying causes of death among them, by reviewing multiple-causes-of-death records. Standardised mortality ratios (SMRs) and 95% confidence intervals were calculated to compare the distribution of causes to that among the same-age general population of deceased persons. The geographical distribution was also evaluated.


RESULTS
Of the 946 deaths among persons with CKS, 65.9% were attributable to non-neoplastic conditions and 21.9% to malignancies. For 12.2%, no lethal pathology was identified and CKS was considered as the underlying cause. In 90% of these cases, there was visceral/nodal involvement, therapy-related complications, or neoplastic cachexia. Among persons with CKS who died of other causes, an excess for lymphoid malignancies emerged (SMR=4.40) (chronic lymphocytic leukaemia (11.03), non-Hodgkin's lymphoma (4.22), Hodgkin's lymphoma (11.80), and multiple myeloma (2.3)), balanced by a deficit for all solid cancers (0.56), with a marked deficit for lung cancer (0.41). We found an excess for respiratory diseases (chronic obstructive pulmonary disease (1.86)) and genitourinary diseases (chronic renal failure (6.47)). There was marked geographical heterogeneity in the distribution of deaths.


CONCLUSIONS
Though referring specifically to Italy, the results are informative for other countries and populations and all cases of CKS in general.
Ascoli
V
V
Dipartimento di Medicina Sperimentale, Università La Sapienza, Viale Regina Elena 324, 00161 Rome, Italy. valeria.ascoli@uniroma1.it
Minelli
G
G
Kanieff
M
M
Crialesi
R
R
Frova
L
L
Conti
S
S
D000368:Aged; D000369:Aged, 80 and over; D002423:Cause of Death; D005260:Female; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008297:Male; D012514:Sarcoma, Kaposi / Q000401:mortality*; D013997:Time Factors
Clin Microbiol Infect. 2003 Apr;9(4):274-9
12667236
IARC Sci Publ. 1987;(82):1-406
3329634
J Med Virol. 2005 Aug;76(4):571-5
15977229
Cancer. 1994 Nov 15;74(10):2873-8
7954250
J Natl Cancer Inst. 2002 Nov 20;94(22):1712-8
12441327
Br J Cancer. 2009 Mar 10;100(5):840-7
19223894
J Natl Cancer Inst. 1995 Jul 5;87(13):1015-7
7629871
Dermatology. 1995;191(2):104-8
8520054
Cancer. 2006 Jan 15;106(2):413-9
16353205
Br J Dermatol. 2002 Nov;147(5):1029-31
12410728
Int J Cancer. 1999 Jan 18;80(2):178-82
9935196
Parassitologia. 2002 Jun;44(1-2):123-9
12404820
Wkly Epidemiol Rec. 1994 Sep 16;69(37):273-5
7986696
Br J Cancer. 2000 Feb;82(3):702-4
10682685
Neuroimmunomodulation. 2008;15(4-6):224-40
19047800
Haematologica. 2002 Apr;87(4):339-43
11940475
Int J Cancer. 1988 Sep 15;42(3):346-51
3417362
Br J Cancer. 2005 Jan 17;92(1):188-93
15570306
Med Vet Entomol. 2006 Jun;20(2):198-208
16871701
Am J Epidemiol. 1986 Aug;124(2):161-79
3524199
Lancet. 2007 Jul 7;370(9581):59-67
17617273
Eur J Dermatol. 2003 Jan-Feb;13(1):83-6
12609790
Int J Cancer. 2000 Feb 15;85(4):453-6
10699913
Br J Cancer. 2001 Aug 3;85(3):379-82
11487269
Am J Epidemiol. 2007 Jul 1;166(1):104-8
17426040
Int J Cancer. 1999 Jan 18;80(2):173-7
9935195
Int J Cancer. 1997 Dec 10;73(6):840-3
9399663
Blood. 2001 Sep 15;98(6):1979-81
11535538
Am J Epidemiol. 1994 Feb 15;139(4):362-8
8109570
Ren Fail. 2007;29(1):107-10
17365919
Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3435-43
19064559
BMC Med Res Methodol. 2005 Jan 17;5(1):4
15655070
Br J Cancer. 1996 Dec;74(11):1812-4
8956798
Mod Pathol. 2008 May;21(5):572-82
18376387
Eur J Cancer. 2007 Sep;43(14):2117-23
17764927
J Hum Virol. 1998 Mar-Apr;1(3):207-13
10195244